Katherine D. Crew, M.D., M.S. is an Assistant Professor of Medicine and Epidemiology at the NewYork-Presbyterian/Columbia University Medical Center. Dr. Crew cares for patients with breast cancer and women at high-risk for breast cancer.
Dr. Crew received her undergraduate B.S. in Biochemistry from Brown University, where she graduated Magna Cum Laude. She received her M.D. from Columbia University College of Physicians and Surgeons and her M.S. from Columbia University School of Public Health. She completed her Internal Medicine residency and Medical Oncology fellowship at NewYork-Presbyterian/Columbia University Medical Center. Dr. Crew is currently involved in patient care, clinical research, and teaching on the Breast Oncology service.
Please contact the doctor's office to verify that your insurance is accepted.
Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care]
Amida Care [Special Needs Plan]
Cigna [EPO, Great West, HMO, POS, PPO]
Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, POS, PPO, Select Care (Exchange), Vytra]
Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
Fidelis Care [Child/Family Health Plus, Medicaid Managed Care]
Healthfirst [Child/Family Health Plus, Medicaid Managed Care]
Oxford Health Plans [Freedom, Liberty]
UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, HMO, Medicaid (Community Plan), POS, PPO, The Empire Plan (NYSHIP)]
VNSNY CHOICE [SelectHealth]
Columbia University College of Physicians and Surgeons
Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
Kukafka R, Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, David R, Crew KD (2015). Breast cancer risk by the numbers: Evaluation of a decision aid in multi-ethnic low-numerate women. Journal of Medical Internet Research (in press).
Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL, Meyskens FL, Moinpour CM (2015). Randomized multicenter placebo-controlled trial of omega-3-fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain (S0927). Journal of Clinical Oncology (in press).
Crew KD, Xiao T, Thomas PS, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice S, Kranwinkel G, Hershman DL (2015). Safety, feasibility, and biomarker effects of vitamin D supplementation among women at high-risk for breast cancer. International Journal of Food Sciences (in press).
Ho KA, Cardelli JA, McLarty J, Hershman DL, Maurer M, Kalinsky K, Taback B, Hibshoosh H, Su T, Refice SF, Crew KD (2015). Evaluating tissue biomarker effects of an oral green tea extract, Polyphenon E, using reverse phase protein array in women with operable breast cancer. International Journal of Food Sciences (in press).
Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew D, Hansen L, Hershman DL (2015). Methods to standardize a multicenter acupuncture trial protocol to reduce aromatase inhibitor-related joint symptoms in breast cancer patients. Journal of Acupuncture and Meridian Studies (in press).
Lue JK, Crew KD (2015). Vitamin D and reduction of breast cancer risk. Current Breast Cancer Reports (in press).
Crew KD (2015). Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. ASCO Educational Book (in press).
Trivedi MS, Hershman DL, Crew KD (2015). Management of chemotherapy-induced peripheral neuropathy. American Journal of Hematology/Oncology (in press).
Reimers LL, Sivasubramanian PS, Campbell J, Greenlee H, Terry MB, Hershman DL, Maurer M, Kalinsky K, Awad D, Xiao T, Sandoval R, Alvarez M, Quirarte A, Crew KD (2015). Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast Journal [Epub ahead of print].
Reimers LL, Crew KD, Terry MB (2015). Atypical hyperplasia of the breast. New England Journal of Medicine, 372:1270-1271.
Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD (2015). Vitamin D-related genes, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control, 26:187-203.
McCullough LE, Eng SM, Bradshaw PT, Cleveland RJ, Steck SE, Terry MB, Shen J, Crew KD, Rossner P, Ahn J, Ambrosone CB, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD (2015). Genetic polymorphisms in DNA repair and oxidative stress pathways may modify the association between body size and postmenopausal breast cancer. Annals of Epidemiology, 25:263-269.
Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY, Valdovinos C, Falci L, Wang Q, Crew KD, Santella RM, Hershman DL, Greenlee H (2015). Dietary modifications, weight loss and changes in metabolic markers effect global DNA methylation in Hispanic, African American and Afro-Caribbean breast cancer survivors. The Journal of Nutrition, 145:783-790.
Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL (2014). Effects of an oral green tea extract, Polyphenon E, on systemic biomarkers of growth factor signaling in women with a history of hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics [Epub ahead of print].
Crew KD, Campbell J, Reynolds D, Fulton L, Flom J, Liao Y, Tehranifar P, Terry MB (2014). Mammographic density and serum 25-hydroxyvitamin D levels. Nutrition and Metabolism [Epub ahead of print]. [PMCID: PMC3996501]
Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL (2014). Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer Investigations 32:439-444.
Kalinsky K, Crew KD, Maurer M, Refice S, Brafman L, Alvarez M, Sandoval R, Hershman DL (2014). Pre-surgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Investigations 32:150-157.
Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB (2014). Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer. International Journal of Cancer 135:1740-1744. [PMCID: PMC4107003]
Khankari NK, Bradshaw PT, McCullough LE, Teitelbaum SL, Steck SE, Fink BN, Xu X, Ahn J, Ambrosone CB, Crew KD, Terry MB, Neugut AI, Chen J, Santella RM, Gammon MD (2014). Genetic variation in multiple biologic pathways, flavonoid intake, and breast cancer. Cancer Causes Control 25:215-226. [PMCID: PMC3932534]
McCullough LE, Santella RM, Cleveland RJ, Millikan RC, Olshan AF, North KE, Bradshaw PT, Eng SM, Terry MB, Shen J, Crew KD, Rossner P, Teitelbaum SL, Neugut AI, Gammon MD (2014). Polymorphisms in DNA repair genes, recreational physical activity, and breast cancer risk. International Journal of Cancer 134:654-663. [PMCID: PMC3830595]
Hershman DL, Unger JM, Crew KD, Minasian LM, Moinpour CM, Hansen L, Lew DL, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology, 31:2627-2633.
Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Brafman L, Kranwinkel G, Tsai WY, Crew KD (2013). Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment, 138:795-806.
Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB. Differences in mammographic density decline over time in breast cancer cases and women at high risk for breast cancer. Cancer Epidemiology Biomarkers and Prevention, 22:476, 2013.
Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL (2013). Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Supportive Care in Cancer, 21:1077-1087. [PMCID: PMC3810608]
Greenlee H, Crew KD, Mata J, McKinley PS, Rundle A, Zhang W, Yuyan L, Tsai WY, Hershman DL (2013). A pilot randomized controlled trial of a commercial diet and exercise weight loss intervention in minority breast cancer survivors. Obesity, 21:65-76.
Crew KD (2013). Vitamin D: Are we ready to supplement for breast cancer prevention and treatment? ISRN Oncology [Epub ahead of print]. [PMCID: PMC3600307]
Sivasubramanian P, Crew KD (2013). Biomarker endpoints for early-phase cancer-prevention studies. Current Breast Cancer Reports [Epub ahead of print]. [PMCID: PMC3600307]
Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL (2012). Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research, 5:1144-1154. [PMCID: PMC3816771]
Hillyer GC, Neugut AI, Crew KD, Kalinsky K, Maurer M, Rotsides DZ, Danaceau J, Hershman DL (2012). Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: A pilot study. Journal of Oncology Practice, 8:100-104. [PMCID: PMC3439234]
Reimers L, Crew KD (2012). Tamoxifen vs. raloxifene vs. exemestane for chemoprevention. Current Breast Cancer Reports 4:207-215. [PMCID: PMC3744245]
Hershman DL, Weimer LH, Wang A, Brafman L, Fuentes D, Awad D, Crew KD (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment, 125:767-774.
Crew KD, Capodice J, Greenlee H, Brafman L, Fuentes D, Awad D, Hershman DL (2010). Randomized, blinded, controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early stage breast cancer. Journal of Clinical Oncology, 28:1154-1160.
Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew KD, Lobo RA, Hershman DL (2010). Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer, 116:2099-2105. [PMCID: PMC3625425]
Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E (2010). Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Endocrinology and Metabolism, 95:559-566. [PMCID: PMC2840866]
Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009). High prevalence of vitamin D deficiency following supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. Journal of Clinical Oncology 27:2151-2156. [PMCID: PMC2674001]
Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM (2009). Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prevention Research 2:598-604. [PMCID: PMC3077714]
Fu OS, Crew KD, Jacobson JS, Greenlee H, Yu G, Campbell J, Ortiz Y, Hershman DL (2009). Ethnicity and persistent symptom burden in breast cancer survivors. Journal of Cancer Survivorship 3:241-250.
Hershman DL, Cho C, Crew KD (2009). Management of complications from estrogen deprivation in breast cancer patients. Current Oncology Reports 11:29-36.
Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008). Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Journal of Clinical Oncology 26:4739-4745. [PMCID: PMC2653138]
Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, Hershman DL (2007). Racial disparities in treatment and survival of male breast cancer. Journal of Clinical Oncology 25:1089-1098.
Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007). Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer. Journal of Clinical Oncology 25:3877-3883.
Crew KD, Gammon MD, Terry MB, Zhang FF, Zablotska LB, Agrawal M, Shen J, Long CM, Eng SM, Sagiv SK, Tietelbaum SL, Neugut AI, Santella RM (2007). Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk. Cancer Epidemiology, Biomarkers, and Prevention 16:2033-2041.
Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng, SM, Sagiv SK, Tietelbaum SL, Neugut AI, Santella RM (2007). Genetic polymorphisms in apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28:2548-2551.
Crew KD, Capodice J, Greenlee H, Apollo A, Sierra A, Brafman L, Fuentes D, Hershman DL (2007). Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy. Journal of Cancer Survivorship 1:283-291.
Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World Journal of Gastroenterology 12:354-62. [PMCID: PMC4066052]
Crew KD, Neugut AI (2006). Aspirin and NSAIDs: Effects in breast and ovarian cancers. Current Opinion in Obstetrics and Gynecology 18:71-75.
Crew KD, Cohen MH, Smith DH, Tiersten AD, Feirt NM, Hershman DL (2005). Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: A case report and review of the literature. Gynecologic Oncology 96:235-40.
Crew KD, Neugut AI (2004). Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology 31:450-64.
Nichols G, de Castro K, Wei L-X, Griffin M, Lin N, Oratzi A, Murty VVVS, Troxel A, Vahdat L, Hesdorffer C (2002). Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia 16:1673-1679.
Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP, Danielpour D, Wakefield LM (1999). Loss of responsiveness to transforming growth factor b induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Research 59:4834-4842.
Wharton KA, Cook JM, Torres-Schumann S, de Castro K, Borod E, Phillips DA (1999). Genetic analysis of the bone morphogenetic protein-related gene, gbb, identifies multiple requirements during Drosophila development. Genetics 152:629-40.
Herbert Irving Pavilion
161 Fort Washington AvenueNew York, NY 10032
Phone: (212) 305-5098
Fax: (212) 305-0178
Assistant Professor of Medicine at CUMC
Assistant Professor of Epidemiology at CUMC
1996-1997 Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Laboratory of Chemoprevention, National Cancer Institute
2003-2005 Full Scholarship for Masters in Biostatistics, Patient Oriented Research Track, Mailman School of Public Health, Columbia University
2006 Southwest Oncology Group Young Investigators Training Course
2006-2010 NIH Loan Repayment Program Award